{"organizations": [], "uuid": "79ce301f14501e23776a5d5c3fa119cb30b399df", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-adamis-pharmaceuticals-updates-sym/brief-adamis-pharmaceuticals-updates-symjepi-commercialization-plans-idUSASB0C7AI", "country": "US", "domain_rank": 408, "title": "BRIEF-Adamis Pharmaceuticals Updates Symjepi Commercialization Plans", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-23T16:12:00.000+02:00", "replies_count": 0, "uuid": "79ce301f14501e23776a5d5c3fa119cb30b399df"}, "author": "", "url": "https://www.reuters.com/article/brief-adamis-pharmaceuticals-updates-sym/brief-adamis-pharmaceuticals-updates-symjepi-commercialization-plans-idUSASB0C7AI", "ord_in_thread": 0, "title": "BRIEF-Adamis Pharmaceuticals Updates Symjepi Commercialization Plans", "locations": [], "entities": {"persons": [{"name": "adamis", "sentiment": "none"}], "locations": [], "organizations": [{"name": "brief-adamis pharmaceuticals updates symjepi commercialization plans reuters", "sentiment": "negative"}, {"name": "adamis pharmaceuticals corp", "sentiment": "none"}, {"name": "adamis pharmaceuticals corp", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 15 PM / in 9 minutes BRIEF-Adamis Pharmaceuticals Updates Symjepi Commercialization Plans Reuters Staff Feb 23 (Reuters) - Adamis Pharmaceuticals Corp: * ADAMIS PHARMACEUTICALS UPDATES SYMJEPI COMMERCIALIZATION PLANS * ADAMIS PHARMACEUTICALS CORP - COMMERCIALIZATION PROCESS FOR SYMJEPI IS STILL ONGOING * ADAMIS PHARMACEUTICALS CORP - NOW IN DISCUSSIONS WITH TWO POTENTIAL PARTNERS FOR SYMJEPI COMMERCIALIZATION Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)", "external_links": [], "published": "2018-02-23T16:12:00.000+02:00", "crawled": "2018-02-23T16:33:31.025+02:00", "highlightTitle": ""}